Lupin rolls out HIV drug Darunavir in US

Published On 2023-06-05 05:00 GMT | Update On 2023-06-05 06:25 GMT

Mumbai: Global pharma major, Lupin Limited, has announced the launch of Darunavir Tablets, 600 mg and 800 mg. The product is a generic equivalent of Prezista Tablets of Janssen Products, LP.

Darunavir Tablets are used in controlling HIV infection.

Darunavir Tablets, 600 mg and 800 mg (RLD Prezista) had estimated annual sales of USD 308 million in the U.S. (IQVIA MAT March 2023).

Medical Dialogues team had earlier reported that the company had received tentative approval from the United States Food and Drug Administration (USFDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Lupin rolls out HIV drug Darunavir in US

Similar News

Syngene International plans to add bioconjugation suite for end-to-end Antibody-Drug conjugates development

CDSCO Panel Rejects Troikaa Pharma's High-Strength Paracetamol Injection Citing Safety Concerns

CDSCO Flags Besto-Cof Cough Syrup as Spurious, Raipur Drug Lab Claims Batch Not Made by Listed Firm

Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide

CDSCO Ends Emergency-Use Authorization of Baricitinib for COVID-19 Treatment

Merck gets USFDA priority review for 2 applications for Keytruda, Keytruda Qlex in combo with Padcev for bladder cancer

CDSCO Flags 112 Drug Batches Including Telmisartan, Pantoprazole, Cefixime, Glimepiride as Not of Standard Quality

Zydus bags Health Canada approval for Mesalamine suppositories for active ulcerative proctitis